A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib-Reference-Cited by-同舟云学术

A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib

Published:2009-03 Issue:3 Volume:31 Page:586-599
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Derks Michael,Fowler Stephen,Kuhlmann Olaf

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference15 articles.

1. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110:763];Grundy;Circulation,2004

2. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men;Goldbourt;Arterioscler Thromb Vasc Biol,1997

3. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study;Schaefer;J Lipid Res,1994

4. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport;Assmann;Atherosclerosis,1996

5. Molecular regulation of HDL metabolism and function: Implications for novel therapies;Rader;J Clin Invest,2006

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib;ACS Omega;2021-06-17

2. The influence of multiple oral administration on the pharmacokinetics and distribution profile of dalcetrapib in rats;Xenobiotica;2020-08-20

3. Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib;Clinical Pharmacokinetics;2018-05-05

4. Present therapeutic role of cholesteryl ester transfer protein inhibitors;Pharmacological Research;2018-02

5. Success, Failure, and Transparency in Biomarker-Based Drug Development;Circulation: Cardiovascular Quality and Outcomes;2017-06